CMS Expands Medicare Drug Price Negotiations to 25 Medications
CMS expands Medicare drug price controls to 25 medications, achieving $12 billion savings with new Maximum Fair Prices starting 2026 and 2027 for chronic and cancer treatments.
CMS Medicare Drug Price Negotiations Yield $12B Savings on 15 High-Cost Medications
CMS announces $12 billion savings from Medicare drug price negotiations on 15 high-cost medications, effective 2027, enhancing Medicare Part D sustainability.
FDA Reassigns Director of Office of Nonprescription Drugs Amid Strategic Shift
The FDA has reassigned the director of its Office of Nonprescription Drugs to a medical devices leadership role, highlighting a strategic shift toward affordability and regulatory realignment. This change may impact drug approval policies and insurance regulatory compliance.
CMS Announces Significant 2027 Reductions on 15 High-Cost Medicare Drugs
CMS sets 2027 maximum fair prices for 15 high-cost Medicare drugs, cutting costs by up to 85% and saving $12 billion annually under Inflation Reduction Act measures.
Novo Nordisk Faces CMS Drug Price Cuts but New Indications Offer Growth Potential
Novo Nordisk's semaglutide drugs face significant Medicare price reductions under CMS negotiation rules starting 2027, but new indications could drive future revenue growth.
Federal Move to Cut Obesity Drug Prices Expands Medicare Coverage
The federal government lowers obesity drug prices and expands Medicare coverage, impacting millions of patients and primary care providers with new access and cost structure.
Medicare Drug Price Negotiations Yield $12 Billion Savings on 15 Key Medications
New Medicare drug price negotiations under the Inflation Reduction Act cut costs for 15 major medications, saving Medicare $12 billion annually.
U.S. Healthcare and Insurance Outlook for 2026: AI, Policy, and Market Trends
Comprehensive 2026 outlook on U.S. healthcare and insurance sector covering AI adoption, Medicare Advantage growth, pharmaceutical scrutiny, market consolidations, and emerging health equity focus.
Medicare Drug Price Negotiations Cut Costs for 15 Key Medications
New Medicare drug price negotiations reduce government costs on 15 high-spend medications, including cancer and diabetes treatments, saving $12 billion annually.
Trump Administration Secures Medicare Drug Price Cuts for 15 Medications
The Trump administration finalizes agreements reducing Medicare prices for 15 drugs, aiming to save billions and impact Medicare Part D plans and drug affordability policies.